Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Sir, Oropharyngeal candidiasis (OPC) is the most common opportunistic infection occurring in HIV-infected individuals. Infection is often recurrent, requiring long-term prophylactic antifungal therapy. Azole resistance is a problem, and the molecular mechanism has recently been discussed by Martinez et al.1 We report anecdotal evidence of the efficacy of subcutaneous interferon-γ (IFN-γ) in an immunosuppressed patient with drug-resistant oropharyngeal candidiasis and advanced HIV disease. A 31-year-old male patient, diagnosed as HIV positive in 1992, first experienced OPC in 1993 and was treated successfully with oral fluconazole (200 mg/day for 7 days). In 1994 the patient experienced several recurrent episodes of OPC, which were treated with oral fluconazole (200–400 mg/day for 7–14 days). He was not adherent to antiretroviral therapy, despite worsening immunosuppression (CD4+ count <100 cells/mm3). Oral fluconazole 50 mg daily was commenced as prophylactic therapy for OPC. Further recurrences of OPC were treated with oral itraconazole (200 mg twice daily for 21 days) and ketoconazole (200 mg once daily for 14 days) with only partial resolution of symptoms. The patient was admitted to hospital in September 1998 with profound bone marrow hypoplasia secondary to Mycobacterium avium (MAC) infection (treated with clarithromycin, rifampicin and ethambutol). He was highly antiretroviral drug experienced, and his antiretroviral regime at time of presentation was abacavir, lamivudine and stavudine. CD4+ count was 7 cells/mm3 and viral load was 48 000 copies/mL. He continued to have OPC that did not respond to treatment with topical nystatin and amphotericin, and that was found to be clinically and microbiologically resistant to azole antifungals [Candida albicans: fluconazole MIC > 128 mg/L and itraconazole MIC > 16 mg/L; a pre-treatment isolate of C. albicans was susceptible to fluconazole (MIC 2 mg/L) and itraconazole (0.5 mg/L)]. The patient refused intravenous therapy with amphotericin B. It was therefore decided to stimulate macrophage function with IFN-γ 1 mg three times weekly, administered subcutaneously, and to continue topical amphotericin and nystatin. Within 3 weeks of commencing this therapy there was a dramatic improvement in symptoms and signs of OPC. IFN-γ was discontinued after 4 months of treatment, and within 4 days there was recurrence of his symptoms. IFN-γ was therefore reintroduced successfully. IFN-γ (a T cell-derived lymphokine) is a broadly acting host defence-enhancing cytokine. Candida infection may be associated with an insufficient IFN-γ response of the host and it has been demonstrated that peripheral blood mononuclear cells from HIV-infected patients show decreased ability for proliferative and differentiative cytotoxic responses (including the production of IFN-γ) to candidal proteins.2 IFN-γ has antineoplastic effects and indirect antifungal and antiviral activity mediated by immunomodulatory effects. At a cellular level these include macrophage activation, stimulation of antigen presentation through class I and class II major histocompatibility complex molecules, regulation of leucocyte–endothelium interaction, and effects on cell proliferation and apoptosis.3,4 IFN-γ has been demonstrated to have synergic activity with amphotericin B against intracellular Cryptococcus neoformans in animal studies.5 The proposed mechanisms by which IFN-γ exerts an antifungal effect are by increasing production of reactive oxygen radicals, which increases the candidacidal activity of granulocytes, and by inhibition of phagocytosis. In vitro studies have demonstrated that IFN-γ can reduce endothelial cell phagocytosis by 41.3% compared with untreated endothelial cells.6 As yet there have been no reported clinical trials of IFN-γ in HIV-infected patients with azole-resistant OPC. These patients (such as the patient described above and the patient described by Martinez et al.1) may benefit from the use of immunological therapy such as IFN-γ in combination with antifungal therapy. Corresponding author. Tel: +44-141-211-1094; Fax: +44-141-211-1097; E-mail: neenabodasing@hotmail.com 1The Brownlee Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN; 2Mycology Reference Laboratory, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK; 3Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fratti, R. A., Ghannoum, M. A., Edwards, J. E., & Filler, S. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.11.4714-4718.1996 · Cited by 46
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“colony-stimulating factor [266] and IFN-g [267] have been”
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“(rGM-CSF) [272] and INF-g [273] have been used for refrac-”
MethodInterferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series
Delsing, C. E., Gresnigt, M. S., Leentjens, J., Preijers, F., Frager, F. A., Kox, M., Monneret, G., Venet, F., Bleeker-Rovers, C. P., van de Veerdonk, F. L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-166 · Cited by 271
Noncanonical Fungal Autophagy Inhibits Inflammation in Response to IFN-γ via DAPK1
Oikonomou, V., Moretti, S., Renga, G., Galosi, C., Borghi, M., Pariano, M., Puccetti, M., Palmerini, C. A., Amico, L., Carotti, A., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.10.012 · Cited by 68
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50
Metadata
- Authors
- Bodasing, N.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-08
- Volume
- 50
- Issue
- 5
- Pages
- 765-766
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2168225065
- Cited by
- 31
- References
- 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.